MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-02-2023
NuVasive Book Value 2011-2026 | NUVA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value NuVasive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.22 B | 2.15 B | 2.69 B | 915 M | 835 M | 799 M | 701 M | 702 M | 648 M | 605 M | 538 M | 505 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.69 B | 505 M | 1.11 B |
Quarterly Book Value NuVasive
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.09 B | 2.17 B | 2.22 B | 2.17 B | - | 2.16 B | 2.15 B | 2.13 B | 2.15 B | 2.16 B | 2.69 B | 2.69 B | 2.69 B | 2.69 B | 1.89 B | 1.89 B | 1.89 B | 1.89 B | 1.71 B | 1.71 B | 1.71 B | 1.71 B | 1.64 B | 1.64 B | 1.64 B | 1.64 B | 1.57 B | 1.57 B | 1.57 B | 1.57 B | 1.3 B | 1.3 B | 1.3 B | 1.29 B | 1.34 B | 1.34 B | 1.34 B | 1.34 B | 1.18 B | 1.18 B | 1.18 B | 1.18 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 1.12 B | 1.12 B | 1.12 B | 1.12 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.69 B | 1.12 B | 1.67 B |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
3.85 B | $ 190.07 | 2.73 % | $ 14.2 B |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | USA |
 |
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.66 | 0.64 % | $ 1.71 B | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M |  China |
 |
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | USA |
 |
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
40.9 M | $ 3.49 | -2.79 % | $ 131 M |  France |
 |
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | USA |
 |
Boston Scientific Corporation
BSX
|
43.7 B | $ 64.23 | 1.28 % | $ 95.1 B | USA |
 |
Electromed
ELMD
|
43.2 M | $ 26.06 | 2.64 % | $ 220 M | USA |
 |
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.66 | 8.2 % | $ 41.1 M | USA |
 |
ClearPoint Neuro
CLPT
|
28 M | $ 11.79 | 12.29 % | $ 334 M | USA |
 |
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
101 M | - | - | $ 10.2 M | USA |
 |
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
347 M | $ 16.75 | 1.33 % | $ 393 M | USA |
 |
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | USA |
 |
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | USA |
 |
LENSAR
LNSR
|
-12.2 M | $ 5.93 | 2.24 % | $ 70.9 M | USA |
 |
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M |  Canada |
 |
Globus Medical
GMED
|
4.57 B | $ 95.25 | 2.7 % | $ 12.9 B | USA |
 |
Helius Medical Technologies
HSDT
|
2.35 M | $ 2.12 | 2.91 % | $ 1.29 M | USA |
 |
Butterfly Network
BFLY
|
169 M | $ 5.45 | 3.02 % | $ 1.15 B | USA |
 |
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | USA |
 |
Inogen
INGN
|
192 M | $ 6.82 | 3.49 % | $ 181 M | USA |
 |
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.06 | 1.92 % | $ 18 M | USA |
 |
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
111 M | $ 10.86 | 0.28 % | $ 389 M | USA |
 |
Inspire Medical Systems
INSP
|
781 M | $ 57.59 | 2.02 % | $ 1.69 B | USA |
 |
CONMED Corporation
CNMD
|
1.03 B | $ 39.08 | 3.09 % | $ 1.21 B | USA |
 |
LivaNova PLC
LIVN
|
1.2 B | $ 67.12 | 3.25 % | $ 3.66 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
1.75 B | $ 90.2 | 2.07 % | $ 3.13 B | USA |
 |
FONAR Corporation
FONR
|
146 M | $ 18.8 | 0.21 % | $ 123 M | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 80.99 | 2.45 % | $ 47.4 B | USA |
 |
Sintx Technologies
SINT
|
2.93 M | $ 2.7 | 0.75 % | $ 7.49 M | USA |
 |
Penumbra
PEN
|
1.43 B | $ 332.13 | 0.2 % | $ 12.9 B | USA |
 |
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | USA |